Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
about
Metalloproteinase inhibitors: status and scope from marine organismsGelatinase B/MMP-9 in Tumour Pathogenesis and ProgressionPhosphorylation and Reorganization of Keratin Networks: Implications for Carcinogenesis and Epithelial Mesenchymal TransitionMoving targets: Emerging roles for MMPs in cancer progression and metastasisInhibitory Effect of Aqueous Extracts from Marine Sponges on the Activity and Expression of Gelatinases A (MMP-2) and B (MMP-9) in Rat Astrocyte CulturesNoninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs).Less is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells.Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?Conformational variability of matrix metalloproteinases: beyond a single 3D structure.Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.Angiogenesis and progression in human melanoma.Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptidesMetzincin proteases and their inhibitors: foes or friends in nervous system physiology?Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Targeting angiogenesis in melanoma: prospects for the futureBlockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy.Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis.Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old IdeasExpression of matrix metalloproteinase-10 in non-metastatic prostate cancer: Correlation with an imbalance in cell proliferation and apoptosisFunctional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in gliomaAngiogenesis in melanoma.MMPs as therapeutic targets--still a viable option?Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivoCalculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with MMP-13.Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression.Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects.Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies.Rac and Rho driving tumor invasion: who's at the wheel?Drug resistance associated with antiangiogenesis therapy.Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal MusclesAngiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases.Looking at the proteases from a simple perspective.Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies.Metal complexes and metalloproteases: targeting conformational diseases.Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).Emerging drugs for the treatment of bone metastasis.Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.
P2860
Q21296828-3A115AB2-B185-4C7D-BF1C-B846F9CA0F39Q24568374-31E3D278-EDB7-4E45-B295-E691AE5F950EQ26996336-CA02B2E1-5419-45A7-81D2-3C51610E9B3EQ27008735-3AE9F75C-6E6A-486A-AF7C-BF7A06D1F7F8Q28547985-F74BA626-36DD-4C54-BD20-93F62625594DQ30540289-5D64020A-5DE9-4C83-BAF3-546763F1A545Q30824578-C2A8D107-EEB0-4467-BD89-AE0275571804Q33660754-780BA6A1-DA5C-48F4-8C1E-5C5A500D5FDEQ33691403-4AAD26AE-81A4-4C77-A0B5-135C51296F55Q33936554-EEEA4DA0-71C7-4356-B50C-0553B3E16730Q33958982-6F31630F-9DD4-44E6-A968-C6DACD32054BQ33982978-3DE04ECC-370F-4BDE-AB68-D9B03A70696EQ34285372-C516C98C-81A9-471F-A3C5-09CC12E330D7Q34768858-E94F7FE5-EA4B-488A-9545-996F0FE84918Q34939979-5D53989E-886A-4379-9C3B-E32F30457649Q35076316-732CA5AB-5596-49CA-90D6-F4F9F85B61F4Q35474102-0A563162-8875-41EC-BD63-A3FDA28CFFDBQ35733486-E563105A-7ED7-4450-A4B7-A2843D166E28Q35755517-D99F0125-020B-47E4-95C3-86856B27A59DQ35760031-628DAAD0-CD37-4845-9B0A-BBA1A826AE96Q36216594-7C9A4557-19D6-4389-A536-0FC8FDAC1F40Q36525192-6ED02DF9-0FE6-4842-8069-093AA491A3E5Q36626892-43E2185D-21D9-4189-A41F-1CCC9373210DQ36908023-0175952F-68A4-40A0-932C-5EE3A2AD43E4Q37086127-9B783BC2-3D33-4669-8E4E-4C8B775B0366Q37106249-36AC7DFE-5A66-4490-8735-EFF141491862Q37129586-46E60360-EF4A-4DBF-A7AD-8E84DBBEB65EQ37253560-590EAD1B-CDD4-431A-AA26-F2905091AB72Q37332258-6D847F75-6F08-4366-BF85-3368AB10A0CBQ37416386-586E2493-886D-4BCB-9493-53CB5B733C31Q37518288-2232E61E-762E-4575-A2D3-89ADADB4247CQ37589790-F2993C06-0916-4770-8925-59BB1C05B0E0Q37628695-E1C91A91-1D50-4CD4-980E-373F15B518B5Q37784801-25501618-F253-497B-978D-550EEE8B9DD0Q37848282-52A39164-C9C2-44AD-A12E-1C2968C6DBFEQ38186064-060760CD-F3C8-4F92-8EAC-4B3D680818C6Q38215608-5DE814A2-318A-467F-87BD-F2F95301C29AQ38237471-AFF84524-4585-4913-BEED-FA9CF5169FDEQ38538263-EDC0FE0E-BC18-4DE2-8799-FC928E701BA1Q38670015-4E36E595-9E73-4E89-803D-15510E5EA983
P2860
Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Matrix metalloproteinase inhib ...... of phase III clinical trials.
@ast
Matrix metalloproteinase inhib ...... of phase III clinical trials.
@en
type
label
Matrix metalloproteinase inhib ...... of phase III clinical trials.
@ast
Matrix metalloproteinase inhib ...... of phase III clinical trials.
@en
prefLabel
Matrix metalloproteinase inhib ...... of phase III clinical trials.
@ast
Matrix metalloproteinase inhib ...... of phase III clinical trials.
@en
P356
P1476
Matrix metalloproteinase inhib ...... of phase III clinical trials.
@en
P2093
Maria Pavlaki
Stanley Zucker
P2888
P304
P356
10.1023/A:1023047431869
P577
2003-06-01T00:00:00Z
P6179
1006803463